PL1776377T3 - Nowy steroid, agonista FXR - Google Patents

Nowy steroid, agonista FXR

Info

Publication number
PL1776377T3
PL1776377T3 PL05715596T PL05715596T PL1776377T3 PL 1776377 T3 PL1776377 T3 PL 1776377T3 PL 05715596 T PL05715596 T PL 05715596T PL 05715596 T PL05715596 T PL 05715596T PL 1776377 T3 PL1776377 T3 PL 1776377T3
Authority
PL
Poland
Prior art keywords
fxr
novel steroid
steroid agonist
agonist
novel
Prior art date
Application number
PL05715596T
Other languages
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PL1776377T3 publication Critical patent/PL1776377T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05715596T 2004-02-26 2005-02-28 Nowy steroid, agonista FXR PL1776377T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04004408A EP1568706A1 (en) 2004-02-26 2004-02-26 Novel steroid agonist for FXR
EP05715596A EP1776377B1 (en) 2004-02-26 2005-02-28 Novel steroid agonist for fxr
PCT/EP2005/002086 WO2005082925A2 (en) 2004-02-26 2005-02-28 Novel steroid agonist for fxr

Publications (1)

Publication Number Publication Date
PL1776377T3 true PL1776377T3 (pl) 2009-02-27

Family

ID=34745911

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05715596T PL1776377T3 (pl) 2004-02-26 2005-02-28 Nowy steroid, agonista FXR

Country Status (11)

Country Link
US (1) US7812011B2 (pl)
EP (2) EP1568706A1 (pl)
AT (1) ATE402945T1 (pl)
CY (1) CY1108455T1 (pl)
DE (1) DE602005008611D1 (pl)
DK (1) DK1776377T3 (pl)
ES (1) ES2313305T3 (pl)
PL (1) PL1776377T3 (pl)
PT (1) PT1776377E (pl)
SI (1) SI1776377T1 (pl)
WO (1) WO2005082925A2 (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
ES2609395T5 (es) 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
EP2324046B1 (en) 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
SI2698375T1 (sl) 2008-11-19 2018-10-30 Intercept Pharmaceuticals, Inc. Modulatorji TGR5 in njihova uporaba
US20110257139A1 (en) 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
US8258485B2 (en) * 2010-08-30 2012-09-04 Media Lario Srl Source-collector module with GIC mirror and xenon liquid EUV LPP target system
JP2015521621A (ja) 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN108250264A (zh) 2012-10-26 2018-07-06 英特塞普特医药品公司 制备胆汁酸衍生物的方法
ES2847002T3 (es) * 2013-05-14 2021-07-30 Intercept Pharmaceuticals Inc Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácido de los mismos como moduladores del receptor X farnesoide
CA2914924A1 (en) 2013-06-13 2014-12-18 Fast Forward Pharmaceuticals B.V. Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
ES2846183T3 (es) 2013-09-11 2021-07-28 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B
DK3071696T3 (da) 2013-11-22 2019-10-07 Mina Therapeutics Ltd C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse
US10407462B2 (en) 2014-05-29 2019-09-10 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
AU2015343025A1 (en) 2014-11-06 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs an FXR/TGR5 agonists and methods of use thereof
MX2017006563A (es) 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
WO2016079519A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016079518A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
CA2975257A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
US10457703B2 (en) 2015-03-31 2019-10-29 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
BR112017021311A2 (pt) 2015-04-07 2018-06-26 Intercept Pharmaceuticals Inc composições farmacêuticas para terapia de combinação
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
CN107531743B (zh) * 2015-04-29 2020-05-05 正大天晴药业集团股份有限公司 鹅去氧胆酸衍生物
EP3124080A1 (en) 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetic bile acids for injection lipolysis
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810587A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 制备无定型奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
US10875888B2 (en) 2016-01-28 2020-12-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Steroid derivative FXR agonist
US20170233431A1 (en) 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US11161871B2 (en) * 2016-03-31 2021-11-02 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of obeticholic acid and preparation method therefor
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EA038580B9 (ru) * 2016-05-18 2021-10-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Агонист fxr, представляющий собой производное стероидов
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
TW201802103A (zh) * 2016-07-13 2018-01-16 江蘇恆瑞醫藥股份有限公司 一種奧貝膽酸及其中間體的製備方法
MX2019006165A (es) 2016-11-29 2019-10-14 Enanta Pharm Inc Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
KR20190117632A (ko) 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
KR20190122813A (ko) * 2017-03-08 2019-10-30 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 결정질 형태
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
US11339147B2 (en) 2017-05-26 2022-05-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Lactam compound as FXR receptor agonist
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
US11447773B2 (en) 2017-09-08 2022-09-20 Mina Therapeutics Limited Stabilized HNF4A saRNA compositions and methods of use
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020039449A1 (en) 2018-08-24 2020-02-27 Solara Active Pharma Sciences Limited An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
US20220033391A1 (en) * 2018-11-26 2022-02-03 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Solid form, crystalline form, and crystal form a of fxr agonist, and preparation method and application thereof
EA202193334A1 (ru) 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2021023100A1 (zh) * 2019-08-06 2021-02-11 杜心赟 脱氧胆酸类化合物、药物组合物及其用途
JP2023510274A (ja) 2020-01-15 2023-03-13 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici

Also Published As

Publication number Publication date
EP1776377A2 (en) 2007-04-25
ES2313305T3 (es) 2009-03-01
DK1776377T3 (da) 2008-11-24
CY1108455T1 (el) 2014-04-09
WO2005082925A2 (en) 2005-09-09
PT1776377E (pt) 2008-11-11
US20080039435A1 (en) 2008-02-14
EP1568706A1 (en) 2005-08-31
ATE402945T1 (de) 2008-08-15
EP1776377B1 (en) 2008-07-30
US7812011B2 (en) 2010-10-12
DE602005008611D1 (de) 2008-09-11
WO2005082925A3 (en) 2005-11-24
SI1776377T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
PL1776377T3 (pl) Nowy steroid, agonista FXR
BE2017C018I2 (pl)
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
MY141194A (en) Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
HK1135703A1 (en) Piperidine gpcr agonists
TW200728307A (en) Novel spirochromanone derivatives
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
WO2004007521A3 (en) Bile acid derivatives as agonists of the farnesoid x receptor
NO20080033L (no) Kinolinderivater som NK3-antagonister
WO2006026034A3 (en) Processes for the preparation of isothiazole derivatives
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
SI1578741T1 (sl) Aromatske spojine kot protivnetna imunomodulatorna in antiproliferativna sredstva
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
DE602005026035D1 (en) Festphasenpeptidsynthese
WO2006123229A3 (en) Novel heterocyclic derivatives
UA80905C2 (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
WO2009019719A3 (en) Process for the preparation of 3-aryloxy-3-arylpropanamines